Skip to main content
Erschienen in: World Journal of Surgery 11/2014

01.11.2014

Is the Outcome of a Salvage Surgery for T4 Thoracic Esophageal Squamous Cell Carcinoma Really Poor?

verfasst von: Yasunori Akutsu, Tsuguaki Kono, Masaya Uesato, Isamu Hoshino, Kentaro Murakami, Tomoyoshi Aoyagi, Takumi Ota, Takeshi Toyozumi, Hiroshi Suito, Hiroki Kobayashi, Rintaro Harada, Takashi Uno, Hisahiro Matsubara

Erschienen in: World Journal of Surgery | Ausgabe 11/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Among patients with T4 thoracic esophageal squamous cell carcinoma (TESCC), it is unclear whether the outcomes of late responders who undergo high-dose chemoradiotherapy (CRT) followed by salvage esophagectomy differs from those of early responders who undergo low-dose CRT followed by esophagectomy.

Methods

A total of 153 patients with T4 TESCC were treated with CRT. The first evaluation was performed after 40 Gy of CRT for downstaging. Of these, 28 patients could be downstaged, and underwent subsequent surgery (early responders). For the remaining patients, additional CRT was administered, and patients were re-evaluated after treatment and underwent salvage surgery. In total, 40 patients (early + late responders) were analyzed.

Results

The primary tumors exhibited a grade 3 response in six (21.4 %) of the early responders and two (16.7 %) of the late responders (p = 1.000). The rate of residual tumor in the primary tumor was 80 % (32/40 patients). The proportions of resected lymph nodes and positive metastatic nodes were similar between early and late responders (p = 0.406 and p = 0.859, respectively). The 5-year overall survival rates among the early and late responders were 25.9 and 36.5 %, respectively, and the median survival times were 24.8 and 24.3 months (p = 0.925), respectively. The 5-year cause-specific survival rates in the early and late responder groups were 61.5 and 72.9 % (p = 0.425), respectively.

Conclusion

The outcomes of both early and late responders to CRT were similar, and salvage surgery for T4 TESCC outweighs the risks in patients with T4 TESCC.
Literatur
1.
Zurück zum Zitat Ozawa S, Tachimori Y, Baba H et al (2012) Comprehensive registry of esophageal cancer in Japan, 2004. Esophagus 9:75–98CrossRef Ozawa S, Tachimori Y, Baba H et al (2012) Comprehensive registry of esophageal cancer in Japan, 2004. Esophagus 9:75–98CrossRef
2.
Zurück zum Zitat Akutsu Y, Uesato M, Shuto K et al (2013) The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 Patients. Ann Surg 257(6):102–108CrossRef Akutsu Y, Uesato M, Shuto K et al (2013) The overall prevalence of metastasis in T1 esophageal squamous cell carcinoma: a retrospective analysis of 295 Patients. Ann Surg 257(6):102–108CrossRef
3.
Zurück zum Zitat Griffin SM, Burt AD, Jennings NA (2011) Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg 254:731–736 discussion 736–737PubMedCrossRef Griffin SM, Burt AD, Jennings NA (2011) Lymph node metastasis in early esophageal adenocarcinoma. Ann Surg 254:731–736 discussion 736–737PubMedCrossRef
4.
Zurück zum Zitat Shimada H, Shiratori T, Okazumi S et al (2008) Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg 206:48–56PubMedCrossRef Shimada H, Shiratori T, Okazumi S et al (2008) Have surgical outcomes of pathologic T4 esophageal squamous cell carcinoma really improved? Analysis of 268 cases during 45 years of experience. J Am Coll Surg 206:48–56PubMedCrossRef
5.
Zurück zum Zitat Nabeya Y, Ochiai T, Matsubara H et al (2005) Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Dis Esophagus 18(6):388–397PubMedCrossRef Nabeya Y, Ochiai T, Matsubara H et al (2005) Neoadjuvant chemoradiotherapy followed by esophagectomy for initially resectable squamous cell carcinoma of the esophagus with multiple lymph node metastasis. Dis Esophagus 18(6):388–397PubMedCrossRef
6.
Zurück zum Zitat Miyoshi N, Yano M, Takachi K et al (2009) Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol 99:302–306PubMedCrossRef Miyoshi N, Yano M, Takachi K et al (2009) Myelotoxicity of preoperative chemoradiotherapy is a significant determinant of poor prognosis in patients with T4 esophageal cancer. J Surg Oncol 99:302–306PubMedCrossRef
7.
Zurück zum Zitat de Manzoni G, Pedrazzani C, Pasini F et al (2007) Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol 95:261–266PubMedCrossRef de Manzoni G, Pedrazzani C, Pasini F et al (2007) Chemoradiotherapy followed by surgery for squamous cell carcinoma of the thoracic esophagus with clinical evidence of adjacent organ invasion. J Surg Oncol 95:261–266PubMedCrossRef
8.
Zurück zum Zitat Seto Y, Chin K, Gomi K et al (2007) Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci 98:937–942PubMedCrossRef Seto Y, Chin K, Gomi K et al (2007) Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci 98:937–942PubMedCrossRef
9.
Zurück zum Zitat Akutsu Y, Matsubara H, Shuto K et al (2009) Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg 33:1002–1009. doi:10.1007/s00268-008-9899-8 PubMedCrossRef Akutsu Y, Matsubara H, Shuto K et al (2009) Clinical and pathologic evaluation of the effectiveness of neoadjuvant chemoradiation therapy in advanced esophageal cancer patients. World J Surg 33:1002–1009. doi:10.​1007/​s00268-008-9899-8 PubMedCrossRef
10.
Zurück zum Zitat Shimoji H, Karimata H, Nagahama M et al (2013) Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 37(9):2180–2188. doi:10.1007/s00268-013-2074-x PubMedCrossRef Shimoji H, Karimata H, Nagahama M et al (2013) Induction chemotherapy or chemoradiotherapy followed by radical esophagectomy for T4 esophageal cancer: results of a prospective cohort study. World J Surg 37(9):2180–2188. doi:10.​1007/​s00268-013-2074-x PubMedCrossRef
11.
Zurück zum Zitat Tachibana M, Dhar DK, Kinugasa S et al (2002) Surgical treatment for locally advanced (T4) squamous cell carcinoma of the thoracic esophagus. Dysphagia 17:255–261PubMedCrossRef Tachibana M, Dhar DK, Kinugasa S et al (2002) Surgical treatment for locally advanced (T4) squamous cell carcinoma of the thoracic esophagus. Dysphagia 17:255–261PubMedCrossRef
12.
Zurück zum Zitat Miyata H, Yamasaki M, Takiguchi S et al (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 100:442–446PubMedCrossRef Miyata H, Yamasaki M, Takiguchi S et al (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 100:442–446PubMedCrossRef
13.
Zurück zum Zitat Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRef Minsky BD, Pajak TF, Ginsberg RJ et al (2002) INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 20:1167–1174PubMedCrossRef
14.
Zurück zum Zitat Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627PubMedCrossRef Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 281:1623–1627PubMedCrossRef
15.
Zurück zum Zitat Aoyagi T, Shuto K, Okazumi S et al (2010) Evaluation of the clinical staging of esophageal cancer by using diffusion-weighted imaging. Exp Ther Med 1:847–851 Aoyagi T, Shuto K, Okazumi S et al (2010) Evaluation of the clinical staging of esophageal cancer by using diffusion-weighted imaging. Exp Ther Med 1:847–851
16.
Zurück zum Zitat Takubo K, Makuuchi H, Fujita H et al (2009) Japanese classification of esophageal cancer, tenth edition: part I. Esophagus 6:1–25CrossRef Takubo K, Makuuchi H, Fujita H et al (2009) Japanese classification of esophageal cancer, tenth edition: part I. Esophagus 6:1–25CrossRef
17.
Zurück zum Zitat Takubo K, Makuuchi H, Fujita H et al (2009) Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 6:71–94CrossRef Takubo K, Makuuchi H, Fujita H et al (2009) Japanese classification of esophageal cancer, tenth edition: parts II and III. Esophagus 6:71–94CrossRef
18.
Zurück zum Zitat Markar SR, Karthikesalingam A, Penna M et al (2014) Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol 21(3):922–931PubMedCrossRef Markar SR, Karthikesalingam A, Penna M et al (2014) Assessment of short-term clinical outcomes following salvage esophagectomy for the treatment of esophageal malignancy: systematic review and pooled analysis. Ann Surg Oncol 21(3):922–931PubMedCrossRef
19.
Zurück zum Zitat Murphy CC, Correa AM, Ajani JA et al (2013) Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 17(8):1359–1369PubMedCrossRef Murphy CC, Correa AM, Ajani JA et al (2013) Surgery is an essential component of multimodality therapy for patients with locally advanced esophageal adenocarcinoma. J Gastrointest Surg 17(8):1359–1369PubMedCrossRef
20.
Zurück zum Zitat Piessen G, Messager M, Mirabel X et al (2013) Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg 258:793–800PubMedCrossRef Piessen G, Messager M, Mirabel X et al (2013) Is there a role for surgery for patients with a complete clinical response after chemoradiation for esophageal cancer? An intention-to-treat case-control study. Ann Surg 258:793–800PubMedCrossRef
21.
Zurück zum Zitat Makino T, Doki Y (2011) Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg 17(3):221–228PubMedCrossRef Makino T, Doki Y (2011) Treatment of T4 esophageal cancer. Definitive chemo-radiotherapy vs chemo-radiotherapy followed by surgery. Ann Thorac Cardiovasc Surg 17(3):221–228PubMedCrossRef
22.
Zurück zum Zitat Fujita H, Sueyoshi S, Tanaka T et al (2005) Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg 29:25–30. doi:10.1007/s00268-004-7590-2 discussion 30–31PubMedCrossRef Fujita H, Sueyoshi S, Tanaka T et al (2005) Esophagectomy: is it necessary after chemoradiotherapy for a locally advanced T4 esophageal cancer? Prospective nonrandomized trial comparing chemoradiotherapy with surgery versus without surgery. World J Surg 29:25–30. doi:10.​1007/​s00268-004-7590-2 discussion 30–31PubMedCrossRef
23.
Zurück zum Zitat Welsh J, Settle SH, Amini A et al (2012) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118:2632–2640PubMedCrossRefPubMedCentral Welsh J, Settle SH, Amini A et al (2012) Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer 118:2632–2640PubMedCrossRefPubMedCentral
24.
Zurück zum Zitat Shimada H, Okazumi S, Matsubara H et al (2006) Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 30:1441–1449. doi:10.1007/s00268-005-0462-6 PubMedCrossRef Shimada H, Okazumi S, Matsubara H et al (2006) Impact of the number and extent of positive lymph nodes in 200 patients with thoracic esophageal squamous cell carcinoma after three-field lymph node dissection. World J Surg 30:1441–1449. doi:10.​1007/​s00268-005-0462-6 PubMedCrossRef
25.
Zurück zum Zitat Akutsu Y, Shuto K, Kono T et al (2012) The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol 105:756–760PubMedCrossRef Akutsu Y, Shuto K, Kono T et al (2012) The number of pathologic lymph nodes involved is still a significant prognostic factor even after neoadjuvant chemoradiotherapy in esophageal squamous cell carcinoma. J Surg Oncol 105:756–760PubMedCrossRef
26.
Zurück zum Zitat Akutsu Y, Matsubara H (2013) Lymph node dissection for esophageal cancer. Gen Thorac Cardiovasc Surg 61(7):397–401PubMedCrossRef Akutsu Y, Matsubara H (2013) Lymph node dissection for esophageal cancer. Gen Thorac Cardiovasc Surg 61(7):397–401PubMedCrossRef
27.
Zurück zum Zitat Crosby TD, Brewster AE, Borley A et al (2004) Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90:70–75PubMedCrossRefPubMedCentral Crosby TD, Brewster AE, Borley A et al (2004) Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 90:70–75PubMedCrossRefPubMedCentral
Metadaten
Titel
Is the Outcome of a Salvage Surgery for T4 Thoracic Esophageal Squamous Cell Carcinoma Really Poor?
verfasst von
Yasunori Akutsu
Tsuguaki Kono
Masaya Uesato
Isamu Hoshino
Kentaro Murakami
Tomoyoshi Aoyagi
Takumi Ota
Takeshi Toyozumi
Hiroshi Suito
Hiroki Kobayashi
Rintaro Harada
Takashi Uno
Hisahiro Matsubara
Publikationsdatum
01.11.2014
Verlag
Springer US
Erschienen in
World Journal of Surgery / Ausgabe 11/2014
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-014-2668-y

Weitere Artikel der Ausgabe 11/2014

World Journal of Surgery 11/2014 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.